- Danish drug manufacturer Novo Nordisk, known for its weight loss drug Wegovy, has partnered with OpenAI to accelerate the search for new medications.
- The collaboration aims to bring new and better treatment options to patients faster by leveraging advanced AI capabilities.
- Novo Nordisk will utilize OpenAI's technology to analyze datasets, identify drug candidates and enhance the efficiency of its manufacturing, supply chain and corporate operations.
- The company has assured the public that data will be protected and human oversight will ensure the ethical and compliant use of AI within the partnership.
- Both Novo Nordisk CEO Mike Doustdar and OpenAI CEO Sam Altman expressed optimism that AI can significantly improve patient care and accelerate scientific discovery.
IN FULL
